Incidence and risk factors for structural lung disease following SARS-CoV-2 infection
Autor: | Helmut Prosch, Marco Idzko, Dominik Bernitzky, Daniel Gompelmann, Antje Lehmann, Maximilian Robert Gysan |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
business.industry Incidence (epidemiology) medicine.medical_treatment respiratory system respiratory tract diseases Pulmonary function testing FEV1/FVC ratio Lung disease Oxygen therapy Internal medicine Parenchyma medicine Respiratory system business Prospective cohort study |
Zdroj: | Respiratory infections and bronchiectasis. |
DOI: | 10.1183/13993003.congress-2021.pa3660 |
Popis: | Multiple studies report persistent symptoms following SARS-CoV-2 infection including fatigue, dyspnoea, headache, chest tightness and cough (e.g. Carfi, A. et al. JAMA 2020; 324(6):603-605). Frequency and prognosis of respiratory symptoms, limitations in lung function and persistent changes of lung parenchyma on high-resolution computed tomography (HRCT) following SARS-CoV-2 infection remain unclear. The objective of this study is to determine whether patients develop structural lung disease after recovery from COVID-19. We conduct an ongoing multicentric prospective study assessing patients after confirmed COVID-19. Patients undergo lung function tests and low-dose HRCT at baseline and after 3, 6 and 12 months. In this preliminary analysis, 158 patients aged 47.4 ± 15.8 years (range, 19-91 years) were identified. 44 patients were previously hospitalized. The median hospitalization was 11 days (range, 1-61 days). 65.9% of hospitalized patients (n=29) required oxygen therapy and 11.4% (n=5) required intensive care treatment. Lung function was assessed 17-291 days after confirmed COVID-19 with a median of 82 days. 15.8% of patients showed a reduced FVC In a sample of 158 patients with confirmed COVID-19, one third showed persistent changes on HRCT and a reduction in diffusion capacity approximately 3 months after disease onset. |
Databáze: | OpenAIRE |
Externí odkaz: |